Northwestern Mutual Wealth Management Co. Acquires Shares of 5,101 Regeneron Pharmaceuticals, Inc. $REGN

Northwestern Mutual Wealth Management Co. bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, HoldingsChannel reports. The firm bought 5,101 shares of the biopharmaceutical company’s stock, valued at approximately $3,180,000.

Several other large investors also recently modified their holdings of the business. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $26,000. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $26,000. Titan Wealth CI Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. Finally, Trust Co. of Vermont purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock worth $1,090,030 in the last quarter. Corporate insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Barclays reduced their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Truist Financial raised their target price on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Leerink Partners lifted their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Finally, Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. Sixteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $801.70.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $828.50 on Tuesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $847.00. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $85.30 billion, a P/E ratio of 20.48, a PEG ratio of 1.42 and a beta of 0.22. The stock’s 50 day moving average is $701.36 and its 200 day moving average is $716.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the previous year, the business earned $12.81 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.